BRIDGEWATER, N.J., January 23, 2025--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved memantine ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) stands against the other ...

Barclays analyst Balaji Prasad maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report) today and set a price target of ...

Amneal Pharmaceuticals (AMRX) announced that the FDA has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which ...

Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a drug ...

Reaffirms Annual Forecasts Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus, driven by strong launches and specialty growth.

Amneal Pharmaceuticals Inc (AMRX) stock saw a modest uptick, ending the day at $8.56 which represents a slight increase of $0.30 or 3.63% from the prior close of $8.26. The stock opened at $8.34 and ...

Amneal Pharmaceuticals (AMRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Amneal Pharmaceuticals Inc (AMRX) stock saw a decline, ending the day at $8.26 which represents a decrease of $-0.05 or -0.60% from the prior close of $8.31. The stock opened at $8.35 and touched a ...

Ritholtz Wealth Management decreased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by ...

BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist BRIDGEWATER, N ...